CoChat
Sign Up
Cited by 86

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4+ and CD8+ T Cells in Melanoma Patients

Van Nuffel, An MT, Benteyn, Daphné, Wilgenhof, Sofie, Pierret, Lauranne, Corthals, Jurgen, Heirman, Carlo, van der Bruggen, Pierre, Coulie, Pierre G, Neyns, Bart, Thielemans, Kris, Bonehill, Aude·2012·Molecular Therapy
DOI 10.1038/mt.2012.11
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2012.11

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 48

  1. Eggermont, 2009, Immunotherapy: Vaccine trials in melanoma – time for reflection, Nat Rev Clin Oncol, 6, 256, 10.1038/nrclinonc.2009.42 · DOI
  2. Figdor, 2004, Dendritic cell immunotherapy: mapping the way, Nat Med, 10, 475, 10.1038/nm1039 · DOI
  3. Van Nuffel, 2010, Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation, Methods Mol Biol, 629, 405
  4. Neller, 2008, Antigens for cancer immunotherapy, Semin Immunol, 20, 286, 10.1016/j.smim.2008.09.006 · DOI
  5. Van Tendeloo, 2001, Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells, Blood, 98, 49, 10.1182/blood.V98.1.49 · DOI · Paper page
  6. Mitchell, 2000, RNA-transfected dendritic cells in cancer immunotherapy, J Clin Invest, 106, 1065, 10.1172/JCI11405 · DOI
  7. Mitchell, 2000, RNA transfected dendritic cells as cancer vaccines, Curr Opin Mol Ther, 2, 176
  8. Tuyaerts, 2002, Generation of large numbers of dendritic cells in a closed system using Cell Factories, J Immunol Methods, 264, 135, 10.1016/S0022-1759(02)00099-6 · DOI
  9. Bonehill, 2005, Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy, J Gene Med, 7, 686, 10.1002/jgm.713 · DOI
  10. Knutson, 2005, Tumor antigen-specific T helper cells in cancer immunity and immunotherapy, Cancer Immunol Immunother, 54, 721, 10.1007/s00262-004-0653-2 · DOI
  11. Muranski, 2009, Adoptive immunotherapy of cancer using CD4(+) T cells, Curr Opin Immunol, 21, 200, 10.1016/j.coi.2009.02.004 · DOI
  12. Kreiter, 2008, Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals, J Immunol, 180, 309, 10.4049/jimmunol.180.1.309 · DOI
  13. Bonehill, 2004, Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules, J Immunol, 172, 6649, 10.4049/jimmunol.172.11.6649 · DOI
  14. Su, 2005, Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer, J Immunol, 174, 3798, 10.4049/jimmunol.174.6.3798 · DOI · Paper page
  15. Bonehill, 2009, Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients, Clin Cancer Res, 15, 3366, 10.1158/1078-0432.CCR-08-2982 · DOI
  16. Wilgenhof, 2011, Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma, J Immunother, 34, 448, 10.1097/CJI.0b013e31821dcb31 · DOI
  17. Annunziato, 2009, Heterogeneity of human effector CD4+ T cells, Arthritis Res Ther, 11, 257, 10.1186/ar2843 · DOI · Paper page
  18. Neyns, 2011, A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV), ASCO meeting abstracts
  19. Wolfl, 2007, Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities, Blood, 110, 201, 10.1182/blood-2006-11-056168 · DOI
  20. Seder, 2008, T-cell quality in memory and protection: implications for vaccine design, Nat Rev Immunol, 8, 247, 10.1038/nri2274 · DOI
  21. Betts, 2003, Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation, J Immunol Methods, 281, 65, 10.1016/S0022-1759(03)00265-5 · DOI
  22. Kyte, 2009, Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination, Cancer Immunol Immunother, 58, 1609, 10.1007/s00262-009-0670-2 · DOI
  23. Zennadi, 2001, Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells, Cell Immunol, 210, 96, 10.1006/cimm.2001.1809 · DOI
  24. Campoli, 2008, HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance, Oncogene, 27, 5869, 10.1038/onc.2008.273 · DOI
  25. Van Nuffel, 2012, Epitope and HLA-type independent monitoring of antigen-specific T cells after treatment with dendritic cells presenting full-length tumor antigens, J Immunol Methods, 10.1016/j.jim.2011.12.010 · DOI
  26. Van Tendeloo, 2010, Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination, Proc Natl Acad Sci USA, 107, 13824, 10.1073/pnas.1008051107 · DOI · Paper page
  27. Garcia-Lora, 2003, MHC class I antigens, immune surveillance, and tumor immune escape, J Cell Physiol, 195, 346, 10.1002/jcp.10290 · DOI
  28. Seliger, 2000, Antigen-processing machinery breakdown and tumor growth, Immunol Today, 21, 455, 10.1016/S0167-5699(00)01692-3 · DOI
  29. Bernsen, 2003, On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases, Br J Cancer, 88, 424, 10.1038/sj.bjc.6600703 · DOI
  30. Taramelli, 1986, Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions, Cancer Res, 46, 433
  31. Zhang, 2003, A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein, J Immunol, 171, 219, 10.4049/jimmunol.171.1.219 · DOI
  32. Corbière, 2004, Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors, Tissue Antigens, 63, 453, 10.1111/j.0001-2815.2004.00203.x · DOI
  33. Germeau, 2005, High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens, J Exp Med, 201, 241, 10.1084/jem.20041379 · DOI
  34. Hanagiri, 2006, Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1, Cancer Immunol Immunother, 55, 178, 10.1007/s00262-005-0063-0 · DOI
  35. Lurquin, 2005, Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen, J Exp Med, 201, 249, 10.1084/jem.20041378 · DOI
  36. de Vries, 2005, Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome, J Clin Oncol, 23, 5779, 10.1200/JCO.2005.06.478 · DOI
  37. Lesterhuis, 2011, Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used, Cancer Immunol Immunother, 60, 249, 10.1007/s00262-010-0942-x · DOI
  38. Bonehill, 2008, Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA, Mol Ther, 16, 1170, 10.1038/mt.2008.77 · DOI
  39. Rammensee, 1999, SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics, 50, 213
  40. Di Genova, 2006, Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific, Blood, 107, 2806, 10.1182/blood-2005-08-3255 · DOI
  41. Gnjatic, 2002, CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients, Proc Natl Acad Sci USA, 99, 11813, 10.1073/pnas.142417699 · DOI
  42. Palmowski, 2002, Competition between CTL narrows the immune response induced by prime-boost vaccination protocols, J Immunol, 168, 4391, 10.4049/jimmunol.168.9.4391 · DOI
  43. Worbs, 2007, A key role for CCR7 in establishing central and peripheral tolerance, Trends Immunol, 28, 274, 10.1016/j.it.2007.04.002 · DOI
  44. Wilgenhof, 2010, Clinical outcome following therapeutic vaccination with autologous mRNA electroporated dendritic cell (DC) vaccines in patients with advanced melanoma, ASCO meeting abstracts
  45. Michiels, 2006, Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA, Gene Ther, 13, 1027, 10.1038/sj.gt.3302750 · DOI
  46. Allard, 2008, Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef, Vaccine, 26, 3735, 10.1016/j.vaccine.2008.04.077 · DOI
  47. Breckpot, 2004, Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses, J Immunol, 172, 2232, 10.4049/jimmunol.172.4.2232 · DOI
  48. Frentsch, 2005, Direct access to CD4+ T cells specific for defined antigens according to CD154 expression, Nat Med, 11, 1118, 10.1038/nm1292 · DOI

Cited by

Sorted by citations

See all 86

Metadata

Authors
Van Nuffel, A. M., Benteyn, D., Wilgenhof, S., Pierret, L., Corthals, J., Heirman, C., van der Bruggen, P., Coulie, P. G., Neyns, B., Thielemans, K., & Bonehill, A.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2012-05
Volume
20
Issue
5
Pages
1063-1074
ISSN
1525-0016
DOI
10.1038/mt.2012.11
Cited by
86
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review